Exercise of Options, Issue of Equity & TVR
Instem plc
("Instem", the "Group" or the "Company")
Exercise of Options, Issue of Equity & Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, confirms that it has issued, conditional on admission, 6,480 new ordinary shares, pursuant to an exercise of share options by an employee of the Company on 24 April 2023 ("Share Options") and a further 97,241 new ordinary shares of 10p to be issued to an employee benefit trust ("EBT Shares"), in aggregate 103,721 new ordinary shares of 10 pence each in the Company, together ("New Ordinary Shares"). The EBT Shares have been created in order to satisfy share awards granted in April 2020 under the Company's 2018 LTIP that have now vested.
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the 103,721 New Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00 a.m. on 09 May 2023.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,869,433 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,869,433.
The figure of 22,869,433 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
|
For further information, please contact:
|
|
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 8 hours ago ASOS
- 9 hours ago MJ Gleeson
- 9 hours ago Rolls-Royce Holdings
- 9 hours ago Crest Nicholson Holdings
- 10 hours ago Naked Wines